Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

New Drug Shown to Reduce Size in Both Injected and Metastasized Melanoma Tumors

By BiotechDaily International staff writers
Posted on 02 Apr 2014
A retrospective analysis of patients with metastatic melanoma revealed that a new pharmaceutical agent was shown to reduce the size of injected tumors and also non-injected tumors that had metastasized to other regions of the body.

The analysis documented tumor-level responses from a pivotal phase 3 study evaluating the agent, called talimogene laherparepvec, in patients with injectable unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The findings were presented March 14, 2014, at the Society of Surgical Oncology (SSO) 67th annual Cancer Symposium in Phoenix (AZ, USA).

Talimogene laherparepvec, developed by Amgen (Thousand Oaks, CA, USA), is a research oncolytic immunotherapeutic agent designed to selectively replicate in tumor tissue and to initiate a systemic antitumor immune response. Of the 295 patients treated with talimogene laherparepvec, almost 4,000 tumor lesions were tracked for this analysis. Half of these lesions were injected with the drug at least once, while the rest were not injected, including visceral tumor lesions (tumors involving solid organs such as the lungs and liver). The study’s findings showed a 50% or greater reduction in tumor size in 64% of injected tumors. Furthermore, one-third of uninjected nonvisceral tumors, and 15% of visceral tumors were also reduced by at least 50%. There were 35 melanoma-related surgeries performed during this trial of which 30% successfully removed all residual disease.

The most frequently seen adverse events in the phase 3 study were fatigue, chills and pyrexia. The most common serious adverse events include disease progression in both groups, and cellulitis and pyrexia in the talimogene laherparepvec group. Serious adverse events occurred in 26% of talimogene laherparepvec patients and 13% of GM-CSF patients. Immune-mediated events were reported infrequently.

“These data add to the body of evidence supporting talimogene laherparepvec’s local and distant effect, and its potential ability to stimulate a systemic antitumor immune response,” said Sean E. Harper, MD, executive vice president of research and development at Amgen. “Melanoma remains a devastating and difficult-to-treat disease, and talimogene laherparepvec continues to demonstrate encouraging results in this setting.”

The agent is injected directly into tumor tissue and is intended to replicate preferentially in tumor cells causing lytic cell death and releasing an array of tumor-derived antigens. Talimogene laherparepvec is also engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF), a white blood cell growth factor, which can help to activate the immune system. The aim of this combination of actions is to initiate a systemic antitumor immune response that targets tumor cells throughout the body.

Related Links:

Amgen



WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Exosomes loaded with catalase (shown in red) efficiently interact with neurons (shown in black) to protect them from the effects of Parkinson\'s disease (Photo courtesy of Dr. Elena Batrakova, University of North Carolina).

Exome Delivery of the Anti-Oxidant Catalase Reduces Parkinson's Disease Symptoms in Mouse Model

The exosome delivery of the antioxidant enzyme catalase was shown to dramatically reduce symptoms of Parkinson's disease (PD) in a mouse model. Exosomes are cell-derived vesicles that are present in... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

27 May 2015 - 28 May 2015
02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.